China's First Ultrasound Brain-Computer Interface Company Gestalt Tech Completes 420 Million Yuan Angel+ Round

Product / Tech
โดย Jiemian·Read original
Summary · why it matters

China's first ultrasound brain-computer interface company Gestalt Tech has completed a 420 million yuan angel+ round of financing. This round was led by Huaying Capital, with follow-on investments from C Capital, Sequoia China, Lens Technology, China Electronics Health Fund, Sinovation Ventures, Lingang Sci-Tech Innovation Investment, Fudan Furong Capital, and Guotai Venture Capital, among other leading domestic and international investment institutions. Existing shareholders including Daotong Investment, Yunshi Capital, Qingsong Capital, and Gobi Partners continued to oversubscribe. China Renaissance acted as the exclusive financial advisor. At the same time, Gestalt Tech's Shanghai headquarters in the Brain Intelligence Park in Minhang District was officially inaugurated. As of 14:18 on July 3, 2026, the Shanghai Stock Exchange STAR Biomedical Index rose strongly by 2.69 percent. Among constituent stocks, MGI Tech rose 14.97 percent, Dizal Pharmaceutical rose 10.77 percent, and Olym Biotech rose 8.82 percent, with stocks like Youcare Pharmaceutical and Yundong Biotech also rising. The STAR Medical ETF Huaxia rose 2.17 percent, heading for a fifth consecutive gain, with the latest price at 1.08 yuan. CICC believes that innovative fields represented by AI plus healthcare and brain-computer interfaces are experiencing rapid development, with systems from supporting policies to capital support gradually improving, and such directions may present structural investment opportunities.

Impact on stocks 9

Financials · 1 stocks
China Renaissance Holdings
1911
▲ PositiveCapitalrelevance

China Renaissance acted as exclusive financial advisor for Gestalt Tech's financing round, generating advisory fee income.

Others · 8 stocks
MGI Tech Co. Ltd. A
688114
▲ PositiveDemandrelevance

MGI Tech rose 14.97% as part of a broad rally in STAR Biomedical Index, driven by positive sentiment on AI+healthcare and brain-computer interfaces.

Chengdu Olymvax Biopharmaceuticals Inc. A
688319
▲ PositiveDemandrelevance

Olymvax Biopharmaceuticals rose 8.82% as part of a broad rally in STAR Biomedical Index, driven by positive sentiment on AI+healthcare and brain-computer interfaces.

Theme Impact 1

Off-coverage companies 10

格式塔科技Private▲ Positive
Capitalrelevance

Completed a 420 million yuan angel+ round of financing, a significant capital event for the company.

C Capital (C资本)Private▲ Positive
Capitalrelevance

Participated as a follow-on investor in Gestalt Tech's financing round.

CEC Health Industry FundPrivate▲ Positive
Capitalrelevance

Participated as a follow-on investor in Gestalt Tech's financing round.

Fudan Furong CapitalPrivate± Mixed
relevance

Gobi PartnersPrivate± Mixed
relevance

HongShan (formerly Sequoia Capital China / 红杉中国)Private± Mixed
relevance

Sinovation VenturesPrivate± Mixed
relevance

Yunshi CapitalPrivate± Mixed
relevance

清松资本Private± Mixed
relevance

道彤投资Private± Mixed
relevance

Related news

MIIT outlines action path for AI plus manufacturing; China Southern Fund positions in related industries

At a State Council Information Office press conference on the 15th Five-Year Plan, the Ministry of Industry and Information Technology said it will stay application-driven, deepen the implementation of AI plus manufacturing, support research and development of key technologies such as high-end training chips and multimodal algorithms, tackle frontier technologies including brain-inspired intelligence and world models, advance the iteration of intelligent terminals such as humanoid robots and brain-computer interfaces, and distill high-value scenarios by industry while rolling out a batch of lightweight, low-cost, easy-to-deploy industry solutions. Multiple products under China Southern Fund are positioned in the artificial intelligence industry, including China Southern Digital Economy Mixed Fund, China Southern Technology Pilot Mixed Fund, China Southern Yihe Flexible Allocation Mixed Fund, China Southern Emerging Leaders Flexible Allocation Mixed Fund, and China Southern China Dream Flexible Allocation Mixed Fund.
Jiemian·24dRead more →

MIIT Releases Brain-Computer Interface Standards Guidelines; Over 30 Listed Companies Have Layouts

The Ministry of Industry and Information Technology released on August 24 a draft for comments of the National Brain-Computer Interface Industry Standards System Construction Guidelines 2026 Edition, proposing to formulate or revise more than 40 standards in the brain-computer interface field by 2028 and to promote standards publicity and implementation among over 100 enterprises. In early trading today, consumer sector indices such as daily chemicals, tourism, and hotels and catering led gains, with the daily chemicals industry rising the most. Proya, Betaini, and SYoung Group all gained more than 5 percent, while Qingdao Kingking shot up and sealed the daily limit within two minutes, becoming the only limit-up stock in the daily chemicals sector. Brain-computer interface concept stocks have fallen an average of 15.74 percent this year, but since August the average daily turnover of 10 concept stocks has increased month on month. Beijing Beilu Pharmaceutical had an average daily turnover of 317 million yuan, up 71.83 percent month on month, ranking first. According to statistics from Securities Times Data Treasure, there are currently more than 30 A-share concept stocks involved in the brain-computer interface industry chain, with companies such as Medlander, Vishee, Meihao Medical, Apon Medical, and ZKTeco all having layouts.
数据宝·25dRead more →
10

New Journey plans to acquire 51% of Shandong Zepu for 437 million yuan, with a premium rate exceeding 600%

New Journey announced plans to acquire a 51% stake in Shandong Zepu Medical Technology for 437 million yuan, with the transaction premium rate reaching 615.30%. As of the valuation base date, Shandong Zepu's net asset book value was 77.1475 million yuan, while the income approach valuation reached as high as 552 million yuan. Its technology portfolio spans hot sectors including AI, embodied intelligence, brain-computer interfaces, and rehabilitation robots. Shandong Zepu posted a net loss of 6.4816 million yuan in 2024, turned profitable in 2025 with net profit of 23.4642 million yuan, and recorded net profit of 7.6776 million yuan in the first four months of this year. New Journey's net profit attributable to the parent company fell 73.04% year-on-year to 30.9428 million yuan in 2025, with an asset-liability ratio of 69.73%. The acquisition price will be funded entirely from its own and self-raised funds, and is expected to generate goodwill of approximately 210 million to 240 million yuan.
每日经济新闻·32dRead more →